Evaluation of Ketamine as Sedative Agent in Endoscopic Retrograde Cholangiopancreatography (ERCP)

Recruiting now · Phase 4

Conditions studied: Ketamine Adverse Reaction

In brief

This is a study evaluating the usage of Ketamine as sedative agent in ERCP. The usage of Ketamine will be compared to the standard sedation in our center, which is Midazolam in combination with Pethidine as analgesia.

Key facts

Study ID

NCT04490031

Run by

Universiti Kebangsaan Malaysia Medical Centre

People needed

140

Starts

2020-03-01

Expected to finish

2021-04-30

Last updated by the study team

2020-07-28

Who can join

Age: 16 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Malaysian citizens of who is able to give valid consent
• Patient planned for ERCP (either emergency or elective)

You may not qualify if…

• Known hypersensitivity towards Ketamine or Midazolam
• Patient refusal to participate or unable to give consent
• Increased intracranial pressure, acute stroke (<3 months), intracranial haemorrhage (<3 months)
• Uncontrolled hypertension (BP>160/100) and tachycardia (Heart rate >120)
• Acute myocardial infarction, acute coronary syndrome (<3 months)
• Tachyarrythmia
• Pregnancy
• IVDU or substance abuse patient
• Patient with history of hallucination
• Child's Pugh Class C

Where it is running

• University Kebangsaan Malaysia Medical center — Bandar Tun Razak, Kuala Lumpur, Malaysia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.